AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Aquestive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for Anaphylm (Dibutepinephrine) sublingual film, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [1][4]. Group 1 - The lawsuit is on behalf of investors who acquired securities of Aquestive Therapeutics during the specified period [1]. - Interested parties can submit a form or contact the Investor Relations Manager for more information regarding the lawsuit [2]. - A lead plaintiff must file papers by May 4, 2026, to represent the class in the litigation [3]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigation [5].